Hidetaka Matsuda
Overview
Explore the profile of Hidetaka Matsuda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
121
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nosaka T, Naito T, Akazawa Y, Takahashi K, Matsuda H, Ohtani M, et al.
PLoS One
. 2025 Mar;
20(3):e0314581.
PMID: 40048440
To cure hepatitis B virus (HBV) infection, it is essential to elucidate the function of hepatocyte host factors in regulating the viral life cycle. Signaling and transcription activator of transcription...
2.
Takahashi K, Nosaka T, Murata Y, Sugata R, Akazawa Y, Tanaka T, et al.
DEN Open
. 2025 Feb;
5(1):e70070.
PMID: 39935747
Objectives: The causes of drug-induced gastroduodenal injuries primarily include antithrombotic drugs, including low-dose aspirin, non-steroidal anti-inflammatory drugs, and corticosteroids. These drugs are suspected to affect gastric ulcer healing after endoscopic...
3.
Nosaka T, Murata Y, Akazawa Y, Takahashi K, Naito T, Matsuda H, et al.
Heliyon
. 2024 Aug;
10(14):e34441.
PMID: 39108869
Circulating tumor cells (CTCs) are noninvasive biomarkers that can indicate the therapeutic response and prognosis. The study aimed to investigate the cellular characteristics of CTCs focusing on monitoring during atezolizumab...
4.
Murata Y, Nosaka T, Akazawa Y, Tanaka T, Takahashi K, Naito T, et al.
Cancers (Basel)
. 2024 Jul;
16(13).
PMID: 39001472
Immune checkpoint inhibitors have promising outcomes in patients with hepatocellular carcinoma (HCC); however, there is no reliable biomarker for predicting disease progression. Circulating tumor cells (CTCs) derived from peripheral blood...
5.
Akazawa Y, Ohtani M, Nosaka T, Takahashi K, Naito T, Matsuda H, et al.
Pancreatology
. 2024 Jun;
24(5):698-705.
PMID: 38879434
Background: Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) is one of the most common and serious adverse events associated with ERCP. Thus, we aimed to investigate the usefulness of pre-ERCP pancreatic...
6.
Matsuda H, Nosaka T, Hiramatsu K, Takahashi K, Naito T, Ofuji K, et al.
Clin J Gastroenterol
. 2024 Jun;
17(4):797-798.
PMID: 38839648
No abstract available.
7.
Nosaka T, Murata Y, Akazawa Y, Tanaka T, Takahashi K, Naito T, et al.
Cancers (Basel)
. 2024 May;
16(9).
PMID: 38730737
There remains no reliable biomarker of therapeutic efficacy in hepatocellular carcinoma (HCC) for the PD-L1 inhibitor atezolizumab and bevacizumab (Atezo/Bev). Circulating tumor cells (CTCs) enable the serial collection of living...
8.
Midori Y, Nosaka T, Hiramatsu K, Akazawa Y, Tanaka T, Takahashi K, et al.
Front Cell Infect Microbiol
. 2024 Apr;
14:1371429.
PMID: 38650735
Background: Achieving sustained virologic response (SVR) in patients infected with hepatitis C virus (HCV) reduces all-cause mortality. However, the mechanisms and risk factors for liver fibrosis and portal hypertension post-SVR...
9.
Namikawa S, Nosaka T, Matsuda H, Akazawa Y, Takahashi K, Naito T, et al.
BMC Gastroenterol
. 2023 May;
23(1):169.
PMID: 37217904
Background: Histological evaluation by liver biopsy is considered the gold standard for assessing liver disease; however, it is highly invasive. Non-invasive liver stiffness measurement by shear wave elastography (SWE) is...
10.
Nosaka T, Matsuda H, Sugata R, Akazawa Y, Takahashi K, Naito T, et al.
Curr Oncol
. 2023 May;
30(4):3915-3926.
PMID: 37185409
Background: Proton beam therapy (PBT) has been recently reported to achieve excellent tumor control with minimal toxicity in patients with unresectable hepatocellular carcinoma (HCC). Radiofrequency ablation (RFA) combined with transcatheter...